LadRx | 10-Q: Quarterly report
Xoma to Pay $1M to LadRx as Rare Disease Therapy Undergoes FDA Review
Xoma To Make $1 Mln Milestone Payment To LadRx After FDA Accepts Zevra's NDA For Arimoclomol
LadRx Issues 2024 Update to Shareholders
FDA Acceptance of Arimoclomol Triggers $1 Million Payment LadRx Corporation (OTCQB:LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer
XOMA Acquires Drug Rights From LadRx for $5M
XOMA Acquires Royalty, Milestone Rights for Two Assets From LadRx
XOMA (XOMA) said Thursday it has acquired the royalty and milestone rights for two assets from LadRx for $5 million. The assets are arimoclomol, an investigational treatment for neurogenerative disord
Xoma Has Acquired The Royalty And Milestone Rights Associated With Two Assets From LadRx, Including Arimoclomol And Aldoxorubicin, For $5M, For Orphan Disease Niemann-pick Disease Type C And Phase 2 Oncology, Respectively
Xoma Has Acquired The Royalty And Milestone Rights Associated With Two Assets From LadRx, Including Arimoclomol And Aldoxorubicin, For $5M, For Orphan Disease Niemann-pick Disease Type C And Phase 2 O
LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million With XOMA Corporation
XOMA acquires future milestone economics and royalties associated with arimoclomol and aldoxorubicin, allowing LadRx to focus on core LADR assetsLOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB:
LadRx Announces Reverse Stock Split Effective As Of May 17, 2023 >LADX
LadRx Announces Reverse Stock Split Effective As Of May 17, 2023 >LADX
LadRx To Carry Out 1-for-100 Reverse Stock Split On May 18th, 2023
May 11th - $LadRx(LADX.US)$ is about to implement a 1-for-100 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from May 18th, 2023.$LadRx(LADX.US)$ slipped 5.74%
LadRx Announces Reverse Stock Split >LADX
LadRx Announces Reverse Stock Split >LADX
LadRx, Oncology Drug Developer, Files for Nasdaq Uplisting, Public Offering
LadRx (NASDAQ:CYTR) Now Covered by StockNews.com
Stock analysts at StockNews.com assumed coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report released on Wednesday. The firm set a "hold" rating on the stock.LadRx Stock PerformanceLadRx
LadRx Highlights Patent Issued for Its LADR Technology
LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today hi
Comparing LadRx (OTCMKTS:CYTR) & Inhibrx (NASDAQ:INBX)
LadRx (OTCMKTS:CYTR – Get Rating) and Inhibrx (NASDAQ:INBX – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the streng
LadRx Announces Review of Strategic Alternatives and Provides Corporate Updates
LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announce
Comparing LadRx (OTCMKTS:CYTR) and Inhibrx (NASDAQ:INBX)
LadRx (OTCMKTS:CYTR – Get Rating) and Inhibrx (NASDAQ:INBX – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength o
LadRx (NASDAQ:CYTR) Research Coverage Started at StockNews.com
Stock analysts at StockNews.com assumed coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a research note issued on Sunday. The firm set a "hold" rating on the stock.LadRx Price PerformanceLad
LadRx (OTCMKTS:CYTR) & MiNK Therapeutics (NASDAQ:INKT) Critical Contrast
LadRx (OTCMKTS:CYTR – Get Rating) and MiNK Therapeutics (NASDAQ:INKT – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on
StockNews.com Begins Coverage on LadRx (NASDAQ:CYTR)
StockNews.com started coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report released on Thursday. The brokerage issued a hold rating on the stock. LadRx Stock Performance LadRx has a 52-
No Data